Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma

[1]  L. Staudt,et al.  The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. , 2022, Blood.

[2]  L. Medeiros,et al.  Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge , 2021, Modern Pathology.

[3]  A. Evens,et al.  Defining and Treating High-grade B-cell lymphoma, NOS. , 2021, Blood.

[4]  W. Klapper,et al.  Aggressive B-cell lymphoma cases with 11q aberration patterns indicate a spectrum beyond Burkitt-like lymphoma , 2021, Blood advances.

[5]  R. Rochford.  Reframing Burkitt lymphoma: virology not epidemiology defines clinical variants , 2021, Annals of lymphoma.

[6]  S. Swerdlow,et al.  Mutational Landscape of TdT+ Large B-cell Lymphomas Supports Their Distinction From B-lymphoblastic Neoplasms , 2021, The American journal of surgical pathology.

[7]  Scott E. Smith,et al.  HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. , 2021, Blood advances.

[8]  H. Busch,et al.  Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing , 2021, medRxiv.

[9]  L. Staudt,et al.  CHARACTERIZATION OF THE GENETIC LANDSCAPE OF HIGH‐GRADE B‐CELL LYMPHOMA, NOS – AN LLMPP PROJECT , 2021, Hematological Oncology.

[10]  W. Chan,et al.  Relative frequency and clinicopathologic characteristics of MYC-rearranged follicular lymphoma. , 2021, Human pathology.

[11]  A. Rosenwald,et al.  The “Burkitt-like” immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS , 2021, Virchows Archiv.

[12]  W. Chan,et al.  Double-hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP , 2020, Clinical Cancer Research.

[13]  A. LaCasce,et al.  The treatment of Burkitt lymphoma in adults. , 2020, Blood.

[14]  J. Cerhan,et al.  Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients , 2020, Blood Cancer Journal.

[15]  Ryan D. Morin,et al.  Impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. , 2020, Blood.

[16]  O. Elemento,et al.  Mutation landscape, clonal evolution pattern, and potential pathogenic pathways in B-lymphoblastic transformation of follicular lymphoma , 2020, Leukemia.

[17]  V. Seshan,et al.  Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma. , 2020, Blood advances.

[18]  S. Pileri,et al.  A Spatially Resolved Dark- versus Light-Zone Microenvironment Signature Subdivides Germinal Center-Related Aggressive B Cell Lymphomas , 2020, iScience.

[19]  Ryan D. Morin,et al.  A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. , 2020, Cancer cell.

[20]  Mingzhi Zhang,et al.  High-Grade B-Cell Lymphomas, Not Otherwise Specified: A Study of 41 Cases , 2020, Cancer management and research.

[21]  S. Barrans,et al.  Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit , 2019, Leukemia.

[22]  Ryan D. Morin,et al.  --The double hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH. , 2019, Blood.

[23]  A. Rosenwald,et al.  Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  F. Facchetti,et al.  An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens , 2019, Haematologica.

[25]  Jules N. A. Kerssemakers,et al.  Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma , 2019, Nature Communications.

[26]  Steven J. M. Jones,et al.  Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. , 2019, Blood.

[27]  A. Melnick,et al.  Germinal center‐derived lymphomas: The darkest side of humoral immunity , 2019, Immunological reviews.

[28]  L. Pasqualucci.  Molecular pathogenesis of germinal center‐derived B cell lymphomas , 2019, Immunological reviews.

[29]  P. Koduru,et al.  Bright CD38 Expression by Flow Cytometric Analysis Is a Biomarker for Double/Triple Hit Lymphomas with a Moderate Sensitivity and High Specificity , 2019, Cytometry. Part B, Clinical cytometry.

[30]  Ryan D. Morin,et al.  Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Barrans,et al.  Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  T. Haferlach,et al.  Detailed molecular analysis and evaluation of prognosis in cases with high grade B‐cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements , 2018, British journal of haematology.

[33]  J. Smadbeck,et al.  False-negative rates for MYC fluorescence in situ hybridization probes in B-cell neoplasms , 2018, Haematologica.

[34]  W. Klapper,et al.  IG-MYC + neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas. , 2018, Blood.

[35]  Ryan D. Morin,et al.  High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology. , 2018, Blood advances.

[36]  P. Brousset,et al.  Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements , 2018, Haematologica.

[37]  R. Bociek,et al.  Lymphomas with pseudo-double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations. , 2018, Human pathology.

[38]  E. Jabbour,et al.  High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma , 2018, Modern Pathology.

[39]  A. Davies,et al.  Double hit lymphoma: How do we define it and how do we treat it? , 2018, Best practice & research. Clinical haematology.

[40]  J. Cerhan,et al.  Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements , 2018, Haematologica.

[41]  R. Akyea,et al.  The changing clinical pattern of endemic Burkitt lymphoma in Western Africa: Experience from a tertiary center in Ghana , 2018, Pediatric blood & cancer.

[42]  A. Rosenwald,et al.  High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. , 2018, Blood.

[43]  Stefano Monti,et al.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes , 2018, Nature Medicine.

[44]  Roland Schmitz,et al.  Genetics and Pathogenesis of Diffuse Large B‐Cell Lymphoma , 2018, The New England journal of medicine.

[45]  E. Campo,et al.  Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements , 2018, Modern Pathology.

[46]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[47]  U. Surti,et al.  Further Exploration of the Complexities of Large B-Cell Lymphomas With MYC Abnormalities and the Importance of a Blastoid Morphology , 2017, The American journal of surgical pathology.

[48]  L. Medeiros,et al.  Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature. , 2016, Human pathology.

[49]  Scott E. Smith,et al.  Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable , 2016, British journal of haematology.

[50]  L. Medeiros,et al.  MYC/BCL6 double‐hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis , 2016, Histopathology.

[51]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[52]  Z. Sachs,et al.  Double- and triple-hit lymphomas can present with features suggestive of immaturity, including TdT expression, and create diagnostic challenges , 2016, Leukemia & lymphoma.

[53]  Ken H. Young,et al.  Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma , 2015, Oncotarget.

[54]  C. Copie-Bergman,et al.  MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. , 2015, Blood.

[55]  Shawn M. Gillespie,et al.  Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma. , 2015, Cancer discovery.

[56]  Y. Natkunam,et al.  Expression Profiles of MYC Protein and MYC Gene Rearrangement in Lymphomas , 2015, The American journal of surgical pathology.

[57]  A. Rosenwald,et al.  The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum , 2015, Leukemia.

[58]  L. Medeiros,et al.  B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas , 2015, Modern Pathology.

[59]  Scott E. Smith,et al.  Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. , 2014, Blood.

[60]  E. Engels,et al.  Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study , 2014, AIDS.

[61]  Wenyan Zhang,et al.  HIV-related Burkitt lymphoma with florid granulomatous reaction: an unusual case with good outcome. , 2014, International journal of clinical and experimental pathology.

[62]  Michael L. Wang,et al.  Double hit lymphoma: the MD Anderson Cancer Center clinical experience , 2014, British journal of haematology.

[63]  A. Carbone,et al.  Lymphomas occurring specifically in HIV-infected patients: from pathogenesis to pathology. , 2013, Seminars in cancer biology.

[64]  A. Ariza,et al.  MYC status determination in aggressive B‐cell lymphoma: the impact of FISH probe selection , 2013, Histopathology.

[65]  A. Rosenwald,et al.  MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. , 2013, Blood.

[66]  S. Swerdlow,et al.  Double-hit B-cell Lymphomas With BCL6 and MYC Translocations Are Aggressive, Frequently Extranodal Lymphomas Distinct From BCL2 Double-hit B-cell Lymphomas , 2013, The American journal of surgical pathology.

[67]  N. Gebauer,et al.  ID 3 Mutations Are Recurrent Events in Double-hit B-Cell Lymphomas , 2013 .

[68]  J. Ferlay,et al.  Pediatric, elderly, and emerging adult‐onset peaks in Burkitt's lymphoma incidence diagnosed in four continents, excluding Africa , 2012, American journal of hematology.

[69]  W. Chan,et al.  Gains of MYC locus and outcome in patients with diffuse large B‐cell lymphoma treated with R‐CHOP , 2011, British journal of haematology.

[70]  Philip M Kluin,et al.  Double-hit B-cell lymphomas. , 2011, Blood.

[71]  L. Rimsza,et al.  Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma , 2010, Haematologica.

[72]  Matija Snuderl,et al.  B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma , 2010, The American journal of surgical pathology.

[73]  R. Gascoyne,et al.  MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.

[74]  R. Gascoyne,et al.  Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. , 2009, Blood.

[75]  W. Harrington,et al.  Frequent expression of multiple myeloma 1/interferon regulatory factor 4 in Burkitt lymphoma. , 2009, Human pathology.

[76]  A. Rosenwald,et al.  Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) , 2008, Leukemia.

[77]  S. Yoon,et al.  MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B‐cell lymphoma (DLBCL), especially in germinal centre‐like B cell (GCB) type , 2008, Histopathology.

[78]  F. Jardin,et al.  Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas , 2007, Leukemia.

[79]  Richard Simon,et al.  Molecular diagnosis of Burkitt's lymphoma. , 2006, The New England journal of medicine.

[80]  R. Spang,et al.  A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. , 2006, The New England journal of medicine.

[81]  J. Gerecitano,et al.  Treatment of Burkitt lymphoma in adults , 2006, Expert review of anticancer therapy.

[82]  E. Jaffe,et al.  Granulomatous reaction in Burkitt lymphoma: correlation with EBV positivity and clinical outcome. , 2005, The American journal of surgical pathology.

[83]  B. Nathwani,et al.  AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  E. Haralambieva,et al.  Florid Granulomatous Reaction in Epstein-Barr Virus-positive Nonendemic Burkitt Lymphomas: Report of Four Cases , 2004, The American journal of surgical pathology.

[85]  C. Croce,et al.  Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.